- Conditions
- Acute Hypoxemic Respiratory Failure
- Interventions
- L-Citrulline, Placebo
- Drug
- Lead sponsor
- Asklepion Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 49
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- fMRI, Alcohol Drinking, Alcoholism
- Interventions
- Ghrelin, Placebo, fMRI, Alcohol
- Drug · Procedure
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Colonic Diseases, Cancer
- Interventions
- Oxaliplatin
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 4
- States / cities
- Albuquerque, New Mexico
- Conditions
- Colonoscopy Education
- Interventions
- Not listed
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Head and Neck Cancer
- Interventions
- ZD 1839 500mg
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
- Drug · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure
- Interventions
- Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 15
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more
- Conditions
- Recurrent Medulloblastoma, Recurrent Ependymoma
- Interventions
- Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New York, New York • Cincinnati, Ohio
- Conditions
- Sepsis
- Interventions
- Enteral Dextrose Infusion, Free Water Infusion
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Burns
- Interventions
- Recombinant Factor VIIa, Placebo
- Drug
- Lead sponsor
- United States Army Institute of Surgical Research
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Phantom Limb Pain
- Interventions
- Perineural infusion [continuous peripheral nerve block(s)]
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 4
- States / cities
- Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more
- Conditions
- Glanzmann Thrombasthenia
- Interventions
- EPTACOG BETA
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Delirium, Sleep
- Interventions
- Dexmedetomidine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Trastuzumab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Orlando, Florida • Tampa, Florida + 6 more
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
- Interventions
- Dabrafenib, trametinib, Carboplatin, Vincristine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Months to 17 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 10
- States / cities
- Orange, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Spartalizumab, Capmatinib, spartalizumab placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
- Interventions
- ONCOS-102, Durvalumab, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- San Diego, California • Miami, Florida • Buffalo, New York + 3 more
- Conditions
- Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
- Interventions
- Balanced crystalloid solution volume administration, Packed Erythrocytes Units, Blood Product Unit volume, Plasma volume, Platelets volume
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 6 Months to 15 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 4
- States / cities
- Buffalo, New York • New York, New York • Rochester, New York + 1 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Glucagon, Insulin
- Drug
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 13
- States / cities
- San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Trilaciclib, Sacituzumab Govitecan-hziy
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
- Drug · Radiation
- Lead sponsor
- Julie E. Bauman, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Adenoma, Colonic Neoplasms
- Interventions
- Water Infusion first, CO2 Insufflation First
- Procedure
- Lead sponsor
- White River Junction Veterans Affairs Medical Center
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Farmington, Connecticut • Indianapolis, Indiana